Pharmaceuticals

Abrysvo Or Arexvy Market Forecast With Insights On Demand And Industry Growth

May 5, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Large Will The Abrysvo Or Arexvy Market Be By 2030 Compared To Its 2026 Market Size?

The historical expansion can be attributed to various factors, including the existing unmet demand for RSV vaccines, the rising number of elderly individuals, the significant burden imposed by respiratory infections, the successful granting of regulatory approvals, and increasing public health awareness.

Anticipated expansion during the projection timeframe is driven by an increase in the aging population, a surge in RSV-related hospital admissions, broadened guidelines for vaccination, enhanced accessibility via healthcare providers, and a stronger emphasis on preventative health measures. Key developments expected within this forecast period encompass a heightened focus on preventing RSV, an increase in vaccination rates among the elderly, the broadening of adult immunization campaigns, the implementation of vaccine distribution through hospitals and community channels, and the provision of preventive care for individuals at high risk.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19948&type=smp

What Key Factors Are Affecting The Abrysvo Or Arexvy Market Demand?

The rising incidence of respiratory syncytial virus (RSV) infections is projected to boost the abrysvo or arexvy market going forward. RSV infections, caused by a common virus that primarily affects the respiratory tract, typically lead to mild cold-like symptoms but can result in severe illness for infants, older adults, and immunocompromised individuals. The escalating prevalence of RSV is driven by its highly contagious nature, seasonal outbreaks, insufficient widespread immunity, and increased susceptibility among vulnerable demographics such as infants and the elderly. Abrysvo assists in addressing RSV prevalence by supplying targeted vaccines that safeguard high-risk populations, including older adults and infants, against severe respiratory syncytial virus-related illnesses. To illustrate, in Oct 2024, the Centers for Disease Control and Prevention, a US-based health protection agency, reported that during the 2024-25 season, the overall hospitalization rate linked to RSV reached 3.2 per 100,000 individuals. Thus, the growing prevalence of RSV infections propels the expansion of the abrysvo or arexvy market.

How Is The Abrysvo Or Arexvy Market Segmented Across Different Segment Categories?

The abrysvo or arexvy market covered in this report is segmented –

1) By Clinical Indication: Respiratory Syncytial Virus (RSV) Prevention, Infant Protection

2) By Age Group: Adults (18-59 years), Older Adults (60+ years), Pregnant Individuals (32-36 weeks of gestation)

3) By End User: Healthcare Providers, Pregnant Individuals, High-Risk Adults

What Trends Are Influencing The Abrysvo Or Arexvy Market?

Major companies operating in the abrysvo or arexvy market are focusing on developing advanced products, such as bivalent prefusion F (RSVpreF) vaccines, with the goal of broadening protection, enhancing safety, and addressing high-risk populations. Bivalent RSVpreF vaccines refer to formulations specifically designed to provide immunity against both significant RSV subgroups (RSV-A and RSV-B) by targeting the prefusion state of the fusion (F) protein, a critical site for neutralizing antibodies. For instance, in October 2024, Pfizer Inc., a US-based pharmaceutical company, obtained U.S. Food and Drug Administration (FDA) approval for ABRYSVO (RSV Vaccine), a bivalent RSV prefusion F (RSVpreF) vaccine. This approval was for preventing lower respiratory tract disease in adults aged 18 to 59 at increased risk, thereby expanding its indication to the broadest adult population. It remains the only approved RSV vaccine for pregnant individuals between 32 and 36 weeks of gestation, designed to protect infants from birth to 6 months.

Which Organizations Play A Role In The Abrysvo Or Arexvy Market Landscape?

Major companies operating in the abrysvo or arexvy market are Pfizer Inc., GlaxoSmithKline plc (GSK)

Get The Full Abrysvo Or Arexvy Market Report:

https://www.thebusinessresearchcompany.com/report/abrysvo-or-arexvy-global-market-report

Which Region Is The Top Contributor To The Abrysvo Or Arexvy Market By Share?

North America was the largest region in the abrysvo or arexvy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the abrysvo or arexvy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Abrysvo Or Arexvy Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/abrysvo-or-arexvy-global-market-report

Browse Through More Reports Similar to the Global Abrysvo Or Arexvy Market 2026, By The Business Research Company

Business Intelligence Bi Vendors Market Report 2026

https://www.thebusinessresearchcompany.com/report/business-intelligence-bi-vendors-global-market-report

Financial Analytics Market Report 2026

https://www.thebusinessresearchcompany.com/report/financial-analytics-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795